NASDAQ:ARDX Ardelyx (ARDX) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free ARDX Stock Alerts $7.84 -0.26 (-3.21%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$7.73▼$8.1850-Day Range$7.84▼$9.7452-Week Range$3.16▼$10.13Volume6.13 million shsAverage Volume5.99 million shsMarket Capitalization$1.82 billionP/E RatioN/ADividend YieldN/APrice Target$12.36 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ardelyx alerts: Email Address Ardelyx MarketRank™ Stock AnalysisAnalyst RatingBuy3.14 Rating ScoreUpside/Downside57.6% Upside$12.36 Price TargetShort InterestBearish14.44% of Shares Sold ShortDividend StrengthN/ASustainability-1.32Upright™ Environmental ScoreNews Sentiment0.35Based on 12 Articles This WeekInsider TradingSelling Shares$2.11 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.44) to $0.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.41 out of 5 starsMedical Sector130th out of 946 stocksPharmaceutical Preparations Industry50th out of 434 stocks 4.6 Analyst's Opinion Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.36, Ardelyx has a forecasted upside of 57.6% from its current price of $7.84.Amount of Analyst CoverageArdelyx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.44% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Ardelyx has recently increased by 11.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArdelyx has received a 66.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Constipation medication (A06)" products. See details.Environmental SustainabilityThe Environmental Impact score for Ardelyx is -1.32. Previous Next 2.4 News and Social Media Coverage News SentimentArdelyx has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Ardelyx this week, compared to 4 articles on an average week.Search InterestOnly 51 people have searched for ARDX on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat Follows34 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is an increase of 26% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,109,898.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions58.19% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.44) to $0.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -26.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -26.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 10.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceMake This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…See Why This $3.00 Stock Could Hit $15.00 About Ardelyx Stock (NASDAQ:ARDX)Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Read More ARDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARDX Stock News HeadlinesMarch 19, 2024 | americanbankingnews.comShort Interest in Ardelyx, Inc. (NASDAQ:ARDX) Expands By 11.8%March 16, 2024 | nasdaq.comGuru Fundamental Report for ARDXMarch 19, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 16, 2024 | investorplace.comThe Clock is Ticking: 3 Stocks Set to Explode in the Next QuarterMarch 16, 2024 | ca.finance.yahoo.comARDX Mar 2024 11.000 callMarch 16, 2024 | ca.finance.yahoo.comARDX Mar 2024 8.000 putMarch 16, 2024 | ca.finance.yahoo.comARDX Mar 2024 8.000 callMarch 15, 2024 | finance.yahoo.comARDX Mar 2024 8.500 callMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 15, 2024 | finance.yahoo.comARDX Mar 2024 10.000 putMarch 13, 2024 | seekingalpha.comArdelyx Shrugs Off 'Mixed' Q4 EarningsMarch 12, 2024 | globenewswire.comArdelyx, Inc. Reports Employment Inducement GrantsMarch 12, 2024 | americanbankingnews.comArdelyx, Inc. (NASDAQ:ARDX) Given Consensus Recommendation of "Buy" by BrokeragesMarch 6, 2024 | finance.yahoo.comARDX Mar 2024 12.000 callMarch 6, 2024 | msn.comArdelyx spikes as kidney patient bill advances in CongressMarch 2, 2024 | finance.yahoo.comARDX Mar 2024 7.500 putMarch 2, 2024 | finance.yahoo.comARDX Mar 2024 7.500 callFebruary 28, 2024 | investorplace.comThe Millionaire's Watchlist: 3 Stocks Set for a Meteoric RiseFebruary 27, 2024 | globenewswire.comArdelyx to Participate at the Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | investorplace.comStocks on the Launchpad: The Next 3 Market SensationsFebruary 25, 2024 | sg.finance.yahoo.comQ4 2023 Ardelyx Inc Earnings CallFebruary 23, 2024 | msn.comWhat's Going On With Ardelyx Stock After Earnings?February 23, 2024 | markets.businessinsider.comWhere Ardelyx Stands With AnalystsFebruary 23, 2024 | markets.businessinsider.comArdelyx’s Growth Trajectory: Buoyant Sales Projections and Market Expansion Drive Buy RatingFebruary 23, 2024 | finance.yahoo.comArdelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | finanznachrichten.deArdelyx, Inc.: Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 23, 2024 | markets.businessinsider.comArdelyx’s Ibsrela and Xphozah: Strong Sales and Growth Outlook Justify Buy RatingSee More Headlines Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/19/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARDX CUSIPN/A CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees267Year Founded2007Price Target and Rating Average Stock Price Target$12.36 High Stock Price Target$15.00 Low Stock Price Target$8.50 Potential Upside/Downside+57.6%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,070,000.00 Net Margins-53.08% Pretax Margin-52.65% Return on Equity-43.57% Return on Assets-26.03% Debt Debt-to-Equity Ratio0.30 Current Ratio4.88 Quick Ratio4.64 Sales & Book Value Annual Sales$124.46 million Price / Sales14.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book10.89Miscellaneous Outstanding Shares232,690,000Free Float219,888,000Market Cap$1.82 billion OptionableOptionable Beta0.88 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Michael G. Raab (Age 59)President, CEO & Director Comp: $1.28MMs. Susan Rodriguez (Age 59)Chief Commercial Officer Comp: $760.77kDr. Laura A. Williams M.D. (Age 60)M.P.H., Chief Medical Officer Comp: $873.8kMr. Justin A. Renz CPA (Age 52)MBA, Chief Financial & Operations Officer and Treasurer Comp: $623.7kMr. Robert FelschSenior VP of Finance & Chief Accounting OfficerMs. Elizabeth A. Grammer Esq. (Age 60)Chief Legal & Administrative Officer and Secretary Comp: $623.7kMs. Caitlin LowieVice President of Corporate Communications & Investor RelationsMs. Charon Spencer Sr.Chief Human Resources OfficerMr. David P. Rosenbaum (Age 63)Chief Development Officer Comp: $645.4kMr. Robert C. Blanks (Age 64)Chief Regulatory Affairs & Quality Assurance Officer Comp: $590.8kMore ExecutivesKey CompetitorsAmneal PharmaceuticalsNASDAQ:AMRXHarmony BiosciencesNASDAQ:HRMYSchrödingerNASDAQ:SDGRZai LabNASDAQ:ZLABSyndax PharmaceuticalsNASDAQ:SNDXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,460,246 shares on 3/11/2024Ownership: 5.598%Wellington Management Group LLPBought 106,931 shares on 3/5/2024Ownership: 0.046%American International Group Inc.Bought 8,298 shares on 2/28/2024Ownership: 0.049%David P RosenbaumSold 5,183 sharesTotal: $47,683.60 ($9.20/share)Syon Capital LLCBought 38,900 shares on 2/26/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions ARDX Stock Analysis - Frequently Asked Questions Should I buy or sell Ardelyx stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDX shares. View ARDX analyst ratings or view top-rated stocks. What is Ardelyx's stock price target for 2024? 7 brokerages have issued 1 year price objectives for Ardelyx's stock. Their ARDX share price targets range from $8.50 to $15.00. On average, they anticipate the company's stock price to reach $12.36 in the next twelve months. This suggests a possible upside of 57.6% from the stock's current price. View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts. How have ARDX shares performed in 2024? Ardelyx's stock was trading at $6.20 on January 1st, 2024. Since then, ARDX shares have increased by 26.5% and is now trading at $7.84. View the best growth stocks for 2024 here. Are investors shorting Ardelyx? Ardelyx saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 33,610,000 shares, an increase of 11.8% from the February 14th total of 30,060,000 shares. Based on an average daily trading volume, of 6,570,000 shares, the short-interest ratio is currently 5.1 days. View Ardelyx's Short Interest. When is Ardelyx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our ARDX earnings forecast. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. The biopharmaceutical company had revenue of $34.36 million for the quarter, compared to the consensus estimate of $34.26 million. Ardelyx had a negative trailing twelve-month return on equity of 43.57% and a negative net margin of 53.08%. Ardelyx's revenue was down 22.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.06 EPS. What ETFs hold Ardelyx's stock? ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Direxion Daily S&P Biotech Bull 3x Shares (LABU). What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD). Who are Ardelyx's major shareholders? Ardelyx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.61%), Vanguard Group Inc. (5.60%), Eventide Asset Management LLC (2.93%), Rubric Capital Management LP (1.73%), Price T Rowe Associates Inc. MD (1.00%) and Price T Rowe Associates Inc. MD (1.00%). Insiders that own company stock include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARDX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThe world’s greatest investmentPorter & CompanySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.